Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PALMITATE HYDROCHLORIDE versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PALMITATE HYDROCHLORIDE versus LINCOMYCIN HYDROCHLORIDE.
CLINDAMYCIN PALMITATE HYDROCHLORIDE vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin palmitate hydrochloride is a prodrug that is hydrolyzed in vivo to clindamycin. Clindamycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking peptide bond formation. It also inhibits the early stages of protein synthesis by interfering with the initiation complex.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
150-300 mg orally every 6 hours. Maximum dose: 1.8 g/day.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4–3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8–10 hours.
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Approximately 10% of the dose is excreted unchanged in urine; the remainder is eliminated as inactive metabolites via bile (about 30–40%) and feces (about 50–60%). Renal clearance is minor and dosing adjustment is not typically required in renal impairment.
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic